October 24, 2023
The CDC this week issued new recommendations for providers to help manage a limited supply of a new respiratory syncytial virus (RSV) drug for infants and toddlers.
Earlier this year, the FDA approved nirsevimab, a long-acting monoclonal antibody for babies and high-risk toddlers ahead of respiratory virus season.
The CDC is recommending providers prioritize the 100-milligram dosage to protect infants at highest risk as the agency manages concerns about manufacturing capacity and limited supply of the product.
The manufacturer acknowledged the supply concerns in a statement earlier this month.
“Despite an aggressive supply plan built to outperform past pediatric vaccine launches, demand for this product, especially for the 100 mg doses used primarily for babies born before the RSV season, has been higher than anticipated,” Sanofi said in a statement earlier this month earlier this month.
Here’s what you need to know:
“CDC continues to work with the manufacturer to understand how it may accelerate nirsevimab supply,” the CDC statement says.
The CDC noted providers should follow recommendations from the American Academy of Pediatrics about the use of Palivizumab for eligible infants and children.
HAP encourages everyone to contact their health care provider with questions about the newly available RSV products and to ensure they are ready for the upcoming respiratory virus season.
The CDC’s official health advisory is available online.
Tags: Public Health
Click on topic below for category-specific news articles.
Related Links